Brainsway Ltd. Sponsored ADR $BWAY Shares Sold by Sigma Planning Corp

Sigma Planning Corp reduced its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 49.6% in the third quarter, Holdings Channel.com reports. The fund owned 50,635 shares of the company’s stock after selling 49,800 shares during the quarter. Sigma Planning Corp’s holdings in Brainsway were worth $668,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in BWAY. Masters Capital Management LLC increased its holdings in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after purchasing an additional 650,000 shares during the period. Renaissance Technologies LLC lifted its position in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Y.D. More Investments Ltd increased its holdings in Brainsway by 136.6% during the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after buying an additional 157,042 shares during the period. HWG Holdings LP purchased a new position in shares of Brainsway in the 3rd quarter worth approximately $3,340,000. Finally, Sei Investments Co. increased its position in shares of Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after purchasing an additional 163,925 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.

Brainsway Stock Performance

Shares of Brainsway stock opened at $11.36 on Friday. The business’s 50 day moving average price is $12.95 and its 200 day moving average price is $13.93. The company has a market cap of $457.24 million, a price-to-earnings ratio of 27.11 and a beta of 1.29. Brainsway Ltd. Sponsored ADR has a one year low of $7.14 and a one year high of $17.40.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. The firm had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. On average, analysts predict that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BWAY has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Brainsway in a research note on Friday. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. BTIG Research reiterated a “buy” rating and set a $20.00 price target on shares of Brainsway in a research report on Thursday, September 10th. Weiss Ratings cut Brainsway from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Finally, New Street Research reaffirmed a “buy” rating on shares of Brainsway in a report on Friday, July 24th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Brainsway presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.20.

Brainsway Company Profile

BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.

The company’s Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation.